Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Real-world evaluation of clinical outcomes and long-term survivors in patients with BRAF-V600E metastatic colorectal cancer.
Authors
William Phillips
University of Ottawa, Ottawa, ON, Canada
William Phillips , Mohammad Alrehaili , Horia Marginean , Tim Asmis , Michael M. Vickers , Bryan Lo , Rachel Anne Goodwin
Organizations
University of Ottawa, Ottawa, ON, Canada, Ottawa Hospital Research Institute, Ottawa, ON, Canada, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, Canada, The Ottawa Hospital Regional Cancer Centre, Ottawa, ON, Canada, The Ottawa Hospital Research Institute, Ottawa, ON, Canada, The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada
Research Funding
No funding sources reported
Background: BRAF-V600E mutant metastatic colorectal cancer (BRAF-V600E mCRC) is associated with poor prognosis but confers response to combination BRAF/EGFR blockade. The goal of this study is to evaluate the clinicopathologic features and natural history of BRAF-V600E mCRC in the era prior to combination BRAF/EGFR inhibitors. Methods: This is a retrospective study of patients treated at the Ottawa Hospital Cancer Centre with BRAF-V600E mCRC who did not receive combination BRAF/EGFR therapy. Patients diagnosed with colorectal cancer prior to March 31, 2021, were included. Demographic, clinical, pathologic and cancer characteristics were abstracted from electronic medical records. Outcomes of interest included duration of therapy, as a surrogate of progression free survival, and overall survival (OS). Long-term survivor was defined as OS greater than 2 years. Results: 74 patients were included. Median age was 70 years (IQR=61-78), and 39 (53%) patients were female. There were 17 (23%) patients alive at the end of the follow-up period. 31 (42%) patients had poorly differentiated grade and 26 (35%) were mismatch repair deficient (dMMR). Locations of metastases included liver (40, 54%), peritoneum (30, 41%), lung (18, 24%), bone (5, 7%) and brain (5, 7%). Overall, 64 (86%) patients received first line systemic therapy, 19 (26%) second line, and 5 (7%) third line (see Table). Median duration of therapy in the first line was 4.3 months (IQR=2.0-9.6), second line was 2.9 months (IQR=1.4-4.1), and third line 1.0 months (IQR=1.0-1.9). Overall survival in the entire cohort was 13.2 months (IQR=4.6-25.4). Importantly, 21 (28%) patients were long-term survivors, of which 8 (11%) were dMMR. Conclusions: Patients with BRAF-V600E mCRC generally have poor clinical outcomes with traditional systemic therapies. In this study, we identified approximately 25% of patients who are long-term survivors (OS >2 years). This reflects the real-world heterogeneity of clinical outcomes for patients with BRAF-V600E mCRC who did not receive BRAF/EGFR targeted therapy.
| Treatment | First Line, n=64 | Second Line, n=19 | Third Line, n=5 |
|---|---|---|---|
| Combination Chemotherapy* | 47 (73%) | 11 (58%) | 1 (20%) |
| Singlet chemotherapy | 10 (16%) | 3 (16%) | 1 (20%) |
| Biologic** | 26 (41%) | 3 (16%) | 1 (20%) |
| Pembrolizumab | 4 (6%) | 4 (21%) | 0 (0%) |
*FOLFOX, FOLFIRI, CAPOX, or CAPIRI. **Cetuximab, panitumumab or bevacizumab +/- chemotherapy backbone.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 166)
DOI
10.1200/JCO.2024.42.3_suppl.166
Abstract #
166
Poster Bd #
K14
Abstract Disclosures
Similar Abstracts
Abstract
2023 ASCO Gastrointestinal Cancers Symposium
Phase III FIRE-4 study (AIO KRK-0114): Evaluation of first-line treatment efficacy of FOLFIRI/cetuximab in patients with RAS-WT mCRC receiving the first cycle of treatment with chemotherapy only.
First Author: Sebastian Stintzing
Abstract
2024 ASCO Annual Meeting
Predictors of survival outcome of TAS102 combined with bevacizumab compared to TAS102 alone in Saudi patients with metastatic colorectal cancer beyond second line of systemic therapy.
First Author: Shereef Ahmed Elsamany
Abstract
2022 ASCO Annual Meeting
Real-world (RW) treatment patterns and clinical outcomes for chemotherapy-based regimens in first line (1L) MSI-H/dMMR metastatic colorectal cancer (mCRC).
First Author: Monica Chase
Abstract
2021 ASCO Annual Meeting
A retrospective analysis of real-world time on treatment and overall survival in patients with metastatic colorectal cancer receiving cetuximab in third line.
First Author: Wambui Gathirua-Mwangi